We are live on ! Find out more
TE

Tema ETFs Portfolio holdings

AUM $3.09B
1-Year Est. Return 72.72%
This Fund
S&P 500
This Quarter Est. Return
-2.81%
1 Year Est. Return
+72.72%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$335M
AUM Growth
+$93.9M
Cap. Flow
+$112M
Cap. Flow %
33.58%
Top 10 Hldgs %
28.51%
Holding
174
New
26
Increased
81
Reduced
34
Closed
27

Top Buys

Rank Stock Value
1
TEX icon
Terex
TEX
+$6.33M
2
HRI icon
Herc Holdings
HRI
+$6.32M
3
TKR icon
Timken Company
TKR
+$4.82M
4
BMY icon
Bristol-Myers Squibb
BMY
+$4.37M
5
VMC icon
Vulcan Materials
VMC
+$4.35M

Top Sells

Rank Stock Value
1
PRIM icon
Primoris Services
PRIM
+$7.13M
2
FLR icon
Fluor
FLR
+$5.32M
3
FSS icon
Federal Signal
FSS
+$5.11M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$2.53M
5
ASND icon
Ascendis Pharma A/S
ASND
+$1.85M

Sector Composition

Rank Sector Weight
1 Industrials 43.38%
2 Healthcare 33.02%
3 Utilities 7.31%
4 Technology 5.91%
5 Financials 4.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALEC icon
151
Alector
ALEC
$167M
– –
-14,344
Closed -$27.1K
BNTX icon
152
BioNTech
BNTX
$23.1B
– –
-4,500
Closed -$513K
CLDX icon
153
Celldex Therapeutics
CLDX
$2.77B
– –
-29,480
Closed -$745K
EFX icon
154
Equifax
EFX
$21.1B
– –
-2,354
Closed -$600K
EME icon
155
Emcor
EME
$33.1B
– –
-952
Closed -$432K
EXAS
156
DELISTED
Exact Sciences
EXAS
– –
-15,008
Closed -$843K
FLR icon
157
Fluor
FLR
$6.85B
– –
-107,800
Closed -$5.32M
FSS icon
158
Federal Signal
FSS
$7.11B
– –
-55,272
Closed -$5.11M
JSPR icon
159
Jasper Therapeutics
JSPR
$29.4M
– –
-12,435
Closed -$266K
KROS icon
160
Keros Therapeutics
KROS
$211M
– –
-35,663
Closed -$565K
MLYS icon
161
Mineralys Therapeutics
MLYS
$2.39B
– –
-89,529
Closed -$1.1M
MRNA icon
162
Moderna
MRNA
$24.5B
– –
-9,475
Closed -$394K
PRIM icon
163
Primoris Services
PRIM
$4.66B
– –
-93,374
Closed -$7.13M
SLNO
164
DELISTED
Soleno Therapeutics
SLNO
– –
-13,178
Closed -$592K
SMR icon
165
NuScale Power
SMR
$2.67B
– –
-15,456
Closed -$277K
SRPT icon
166
Sarepta Therapeutics
SRPT
$1.82B
– –
-1,943
Closed -$236K
SRRK icon
167
Scholar Rock
SRRK
$6.33B
– –
-4,836
Closed -$209K
SWTX
168
DELISTED
SpringWorks Therapeutics
SWTX
– –
-30,811
Closed -$1.11M
TERN
169
DELISTED
Terns Pharmaceuticals
TERN
– –
-79,696
Closed -$442K
TYL icon
170
Tyler Technologies
TYL
$13.1B
– –
-408
Closed -$235K
UNP icon
171
Union Pacific
UNP
$179B
– –
-7,413
Closed -$1.69M
VERV
172
DELISTED
Verve Therapeutics
VERV
– –
-89,239
Closed -$503K
ITCI
173
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-3,388
Closed -$283K
NARI
174
DELISTED
Inari Medical, Inc. Common Stock
NARI
– –
-14,790
Closed -$755K
3 4 5 6
7

Similar funds

DCM
Donaldson Capital Management Evansville, Indiana $3.09B AUM 21.24% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.11B AUM 20.67% 1-Year Est. Return
TCG
Tremblant Capital Group West Palm Beach, Florida $3.11B AUM 18.12% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
CAM
Contour Asset Management New York $3.08B AUM 21.94% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.08B AUM 12.07% 1-Year Est. Return
FI
Focused Investors Los Angeles, California $3.08B AUM 12.02% 1-Year Est. Return

Tema ETFs's Q1 2025 Portfolio in Review

As of Q1 2025, Tema ETFs held 174 positions worth $335M, up 39% from $241M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Tema ETFs deployed $112M of net new capital in Q1 2025, opening 26 new positions and adding to 81 existing holdings. Its largest new stake was Bristol-Myers Squibb: 75,050 shares worth $4.58M.

By sector, the portfolio is most concentrated in Industrials at 43% of assets, down from 46% a quarter earlier, followed by Healthcare and Utilities.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $2.53M trimmed.

  • Tema ETFs's largest Q1 2025 buy was Bristol-Myers Squibb: 75,050 shares worth $4.58M.
  • Tema ETFs added most to Terex in Q1 2025, an estimated $6.33M increase.
  • Tema ETFs's biggest Q1 2025 reduction was Alnylam Pharmaceuticals, cutting an estimated $2.53M.
  • Tema ETFs fully exited Primoris Services in Q1 2025, selling an estimated $7.13M.
  • Tema ETFs's ten largest holdings make up 29% of its $335M portfolio in Q1 2025.
  • Tema ETFs opened 26 new positions and closed 27 in Q1 2025.
  • Tema ETFs's portfolio value rose 39% quarter-over-quarter to $335M.

Based on Tema ETFs's 13F filing for Q1 2025, filed 14 May 2025.